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ABSTRACT
Background and aims: Thrombolytic therapy with
intravenous recombinant tissue plasminogen activator (rt-
PA) improves outcome in patients with ischaemic stroke
treated within 3 h of symptom onset, but its extended
implementation is limited. A pilot study was designed to
verify whether evaluation of patients with acute ischaemic
stroke and their treatment with intravenous rt-PA in the
emergency department (ED), followed by transportation
to a semi-intensive stroke care unit, offers a safe and
effective organisational solution to provide intravenous
thrombolysis to acute stroke patients when a stroke unit
(SU) is not available.
Methods: After checking for inclusion and exclusion
criteria, ED doctors contacted the stroke team with a
single page, located family members and urgently
obtained computed tomography scan and laboratory
tests. A stroke team investigator clinically assessed the
patient, obtained written informed consent and super-
vised intravenous rt-PA in the ED. After treatment, the
patient was transferred to the SU for rehabilitation and
treatment of complications, under supervision of the same
stroke team investigator.
Results: 52 patients were treated with intravenous rt-PA
within 3 h of symptom onset. 20 patients (38%) improved
neurologically after 24 h, the number increased to 30
(58%) after one week. At 3 months 22 patients had a
favourable outcome (43%). The 3-month mortality rate
was 12%. Symptomatic cerebral haemorrhage was
observed in two patients (4%).
Conclusions: Intravenous rt-PA administration in the ED
is an effective organisational solution for acute ischaemic
stroke when an SU is not established.
Thrombolytic therapy with intravenous recombi-
nant tissue plasminogen activator (rt-PA) has been
shown to improve outcome in patients with
ischaemic stroke treated within 3 h of symptom
onset.
1 In the United States, however, 69% of
hospitals do not use thrombolysis at all and only
1% of stroke patients receive thrombolytics,
mostly at hospitals with a high volume of stroke
patients.
2 This implies that only immediate referral
of stroke patients to strategically placed, certified,
high-volume stroke centres with continuously
available, dedicated and sophisticated stroke teams,
analogous to the manner in which trauma patients
are routed to certified trauma centres, may increase
the thrombolysis rate.
2
Until recently, the extended use of thrombolytic
therapy with intravenous rt-PA has been prevented
in Europe by concerns about its safety profile, as it
increases the risk of cerebral haemorrhage, and its
efficacy in clinical practice where stroke units (SU)
are not available. The SITS–MOST trial, aiming to
define the risks of rt-PA administration to patients
with acute ischaemic stroke within 3 h of symp-
tom onset in experienced stroke centres in Europe,
has shown a favourable risk–benefit ratio.
3 It is still
debated how to implement thrombolytic therapy,
once its extended use has been approved. In fact,
widespread experience is limited and the number of
SU in most countries is small and unevenly
distributed, so that transportation of the patient
to the closest SU may delay treatment and may
further reduce the number of candidate patients.
In 2000, an SU was not established in our
institution and intravenous rt-PA was not regis-
tered for the treatment of stroke in Italy.
Therefore, we designed a pilot clinical study to
investigate how to implement intravenous throm-
bolysis for the treatment of ischaemic stroke. The
study assessed the safety and outcome of intrave-
nous thrombolysis with rt-PA in the emergency
department (ED), followed by transfer of patients
to a semi-intensive SU for follow-up monitoring,
further treatment and rehabilitation.
METHODS
Stroke team collaboration was established at the
University Hospital of Padua, a large academic city
hospital with more than 100 000 consultations per
year in the ED. The aim of stroke team collabora-
tion was to increase awareness about appropriate
treatments of acute ischaemic stroke (ie, intrave-
nous and intra-arterial thrombolysis, as well as
endovascular procedures). In particular, its aim was
to evaluate how to implement off-label intrave-
nous thrombolysis with rt-PA in acute ischaemic
stroke, before the institution of the SU and the
formal approval of rt-PA in stroke patients by the
European and local regulatory agencies. This pilot
clinical trial was approved by the local Ethical
Committee in 1999 and lasted from 1 January 2000
to 30 June 2007.
The stroke team was composed of internists,
neurologists, neuroradiologists, emergency doctors
and anaesthetists. Its first task was to train the
doctors of the ED about triage and the manage-
ment of patients with acute stroke, so that any
patient admitted to the ED with suspected
ischaemic stroke was immediately triaged by ED
doctors for indications for systemic thrombolysis.
The inclusion/exclusion criteria for thrombolysis
were those of the National Institute of
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1 The most
common reasons against rt-PA treatment were age greater than
80 years, time window greater than 3 h, unclear onset of
symptoms, rapidly improving symptoms, mild stroke (National
Institutes of Health Stroke Scale (NIHSS) score (4), severe
stroke (NIHSS score >25) and pretreatment with anticoagu-
lants. Pretreatment with aspirin or other antiplatelet agents was
not an exclusion criterion. Special attention was paid to exclude
patients with uncontrolled hypertension, but in a few patients
blood pressure control was obtained with one or two small
intravenous labetalol bolus injection(s) before thrombolysis.
1
If the patient fulfilled the inclusion/exclusion criteria, ED
doctors contacted the stroke team on a convenience basis,
mostly between 08:00 and 20:00 hours during weekdays, with a
single page, located family members, urgently obtained a
computed tomography (CT) scan and laboratory tests. One
stroke team investigator, previously authorised by the local
Ethical Committee, convened for clinical assessment, to verify
inclusion/exclusion criteria and to obtain a written informed
consent from the patient or a close relative, while the CT scan
was performed. Neurological deficit on admission was measured
by the NIHSS.
rt-PA (Actilyse, Boehringer Ingelheim, Germany) was admi-
nistered intravenously at a dose of 0.9 mg/kg body weight
(maximum dose 90 mg), with 10% given as a bolus and the
remaining 90% as a constant infusion over one hour under
direct stroke team supervision in the ED. The patients had to be
treated within 3 h from symptom onset.
After thrombolytic infusion, the patients were transferred to
a semi-intensive SU, under supervision of the same stroke team
investigator, to be followed up for the treatment of complica-
tions and rehabilitation. Clinical monitoring was performed
every 2 h for the first 24 h. Blood pressure, heart rate and, when
necessary, oxygen saturation were non-invasively monitored up
to 72 h after stroke or longer, if necessary.
A follow-up CT scan was performed 24 h after thrombolysis
in all patients and whenever the neurological condition
worsened. Further CT or magnetic resonance imaging (MRI)
studies were left to the discretion of the treating doctor. Neither
heparin, aspirin nor other antiplatelet agents were given for
24 h after thrombolysis. Antihypertensive therapy was given
according to the American Heart Association guidelines
4 and our
previous report.
5 Rehabilitation therapy was started within 48 h
after stroke onset.
Early neurological improvement was defined as a decrease of 4
or more points in the NIHSS score from baseline, or complete
resolution of the neurological deficit after 24 h. Early neurolo-
gical deterioration was defined as an increase of 4 or more points
in the NIHSS score in the same time interval.
Telephone or clinic follow-up data were obtained from the
patients and/or caregiver 3 months after treatment. Outcome
was assessed by modified Rankin scale (mRS), 3-month fatality
rate and symptomatic (fatal and non-fatal) intracranial hae-
morrhage (SICH). A good outcome was defined as an mRS score
from 0 to 2, a poor outcome as death or an mRS score from 3 to
5 (death or dependence).
Cerebral bleedings were categorised according to the criteria
published by Fiorelli et al
6 for the European Cooperative Acute
Stroke Study I (ECASS I) cohort: haemorrhagic infarctions with
small petechial haematoma (HI1); haemorrhagic infarctions
with more confluent petechiae (HI2); parenchymal haematoma
less than 30% of the infarcted area with some mild space-
occupying effect (PH1); parenchymal haematoma greater than
30% of the infarcted area with significant space-occupying
effect or clot remote from the infarcted area (PH2). SICH was
defined as any CT/MRI-documented haemorrhage, either
within the infarcted area or in a remote area, concomitant
with an increase of 4 or more points in the NIHSS score. Fatal
SICH was defined as a CT/MRI-detected haemorrhage asso-
ciated with in-hospital death.
Descriptive statistical analysis was performed with SPSS
version 13.0. Continuous variables are expressed as mean ¡ SD
and as median with range for variables with a non-normal
distribution, whereas categorical variables are expressed as
counts and percentages, to make comparisons with the
NINDS results.
1
RESULTS
During the study period (1 January 2000 to 30 June 2007), all ED
consultations for focal neurological deficits were monitored
during five randomly selected weeks. The median number of
hospital admissions per week during the monitoring period was
16 (six for acute ischaemic stroke, four for intracerebral
haemorrhage, two for transient ischaemic attack and four for
other diseases). The median ‘‘symptom to door’’ time was
45 minutes (range 15 minutes to 6 h) and the rate of
intravenous rt-PA treatment in acute ischaemic stroke was 7%.
As patient selection and supervision could be done only by
stroke team investigators authorised by the Ethical Committee,
the study cohort was enrolled on a convenience basis and 52
patients with ischaemic stroke were treated with intravenous
rt-PA. Their clinical characteristics are reported in table 1. They
started treatment within 3 h of symptom onset. In this cohort,
the mean delay between symptom onset and hospital admission
was 39 minutes, from admission to CT 48 minutes and the
median door-to-needle time (delay from admission to rt-PA
treatment) 58 minutes.
Thirty-four patients (65%) were admitted with a moderate
(NIHSS score ,15) and 18 (35%) with a serious stroke (NIHSS
score 15–23). According to the Oxford Community Stroke
Project classification, 15 (29%) were total anterior circulation
infarct, 28 (54%) were partial anterior circulation infarct, six
(11%) were lacunar infarction and three (6%) were posterior
circulation infarct. According to the TOAST classification, the
pathogenesis was cardioembolic in 20 (39%), atherosclerotic in
14 (27%), lacunar in six (11%) and from other or unidentified
causes in 12 (23%).
Table 1 Clinical characteristics of patients enrolled in the present
study, in comparison with the NINDS study
1
Present study NINDS study
Number (% female) 52 (42) 312 (42)
Age, years (SD) 66 (12) 67 (10)
NIHSS score (range) 13 (5–23) 14 (1–37)
Stroke subtypes (%)
Small-vessel occlusive 11 19
Cardioembolic 39 35
Large-vessel occlusive 27 42
Other 23 3
SBP, mm Hg (SD) 147 (22) 155 (22)
DBP, mm Hg (SD) 77 (13) 85 (12)
Glucose, mg/dl (SD) 130 (59) 149 (76)
Mortality within 7 days (%) 3 (6) 16 (5)
Symptomatic haemorrhage (%) 2 (4) 20 (6,4)
DBP, diastolic blood pressure; NIHSS, National Institutes of Health Stroke Scale;
NINDS, National Institute of Neurological Disorders and Stroke; SBP, systolic blood
pressure.
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were in a steady condition and five patients (10%) got worse
(table 2). After one week, 30 patients (58%) improved
neurologically, 14 patients (27%) were in a steady condition
and eight patients (15%) got worse or died. At 3 months, 22
patients (43%) had an mRS of 2 or less (0–2), 29 patients (57%)
had an mRS of 3 or greater (3–5) or had died and one patient
was lost to follow-up.
No complications were observed during intravenous infusion
in the ED, except for minor gingival bleeding in a few patients.
The 3-month mortality rate was 12%: three patients died
within the first week (one from myocardial infarction and two
from respiratory failure) and another three within 3 months
(one from cerebral haemorrhage 7 days after thrombolysis, one
from pulmonary embolism and one from candida sepsis).
Control CT/MRI scan revealed cerebral bleedings in 18
patients (within 24 h from rt-PA administration in seven,
between 1 and 3 days in five, between 4 and 7 days in three,
after 7 days in three). According to the criteria of Fiorelli et al,
6
eight patients had haemorrhagic infarctions with small pete-
chial haematoma (HI1), five had haemorrhagic infarctions with
more confluent petechiae (HI2), two had parenchymal haema-
toma less than 30% of the infarcted area, with some mild space-
occupying effect (PH1) and three had parenchymal haematoma
greater than 30% of the infarcted area with significant space-
occupying effect or in a remote area (PH2). The cerebral
haemorrhage was symptomatic in two patients (4%).
DISCUSSION
Stroke accounts for a high proportion of health-resource
expenses, which are likely to grow with the population ageing.
It is, therefore, important to manage the disease in the most
effective way, as European governments are aiming to contain
healthcare costs and prioritise cost-effective interventions.
7
Thrombolytic therapy can change the clinical course of the
patient with acute ischaemic stroke, but the 3-h time window
requires an efficient organisation and a large number of evenly
distributed SU. The treatment delay is due to the late
recognition of stroke and to the small number of SU with
uneven distribution in the country, so that many patients
cannot be transported to specialised centres with experience in
thrombolysis within the restricted time window.
A clinicalstudy has already shownthatpatients withischaemic
stroke can safely be submitted to thrombolytic therapy in the
setting of a hospital with experience in the treatment of acute
stroke,evenwithoutaneuro-intensivecareunit.
8Patientselection
and the following management have to be coordinated and
continuously monitored, however, as both are of paramount
importanceforthebestclinicaloutcome.
91 0Ourstudyshowsthat
the selection of patients with acute stroke and their treatment
with intravenous rt-PA in the ED is a feasible solution to
implement thrombolytic therapy, as the outcome and rate of
symptomatic haemorrhages are comparable with NINDS data,
provided that: (1) the selection of candidates is based on
experienced stroke triage and doctors with experience in stroke
management; (2) strict collaboration is established between the
EDandstroketeamforcontinuousimprovementofstrokecare,as
recommended by the American Heart Association guidelines;
11 (3)
the patients are submitted to continuous instrumental and
clinical monitoring in the following period of high risk of
recurrence and neurological deterioration; (4) national and
international guidelines are followed with regard to general
management and secondary prevention treatment.
This pilot study has some limitations. First, the patients were
selected only by stroke team investigators, previously authorised
by the Ethical Committee.Inthe future weplan to instructall ED
doctors in the procedure, so that stroke team alert can be avoided.
Second, no patient was treated before 90 minutes. This will be
overcome by a larger number of ED doctors with expertise in this
treatment, which will reduce symptoms-to-needle time. Third,
due to the small number of observations we categorised the
outcome in two categories (mRS 0–2 and 3–5), which limits a full
comparison with the NINDS study.
Our preliminary experience can be geographically expanded
by establishing a network between hospitals. In Germany a
collaborative project aims to extend the use of rT-PA treatment
to non-urban areas through telemedic transport (TEMPiS).
12
The telemedic system consists of a digital network that includes
a video conference focusing on the clinical examination based
on NIHSS and CT/MRI image transfer. Stroke experts may
propose the best treatment options and support the adminis-
tration of intravenous rt-PA, after they have received this
information. On the basis of the results of our study, we
propose that thrombolysis is performed in the ED of first level
outlying hospitals, with the optional support of a stroke team
located in third level hospitals (less numerous and more
specialised) through televideo consultation. After the procedure,
patients can be moved safely to third level referral hospitals to
continue specialised treatment. This ‘‘drip and ship’’ approach
will offer an extended and effective treatment of stroke,
probably at lower costs than if SU were more numerous and
spread over a wide territory.
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Lingual haematoma: a rare
complication of usual warfarin dose
A 66-year-old man presented with lingual oedema of purplish
colour, with pain and swelling and was admitted to the
emergency room. He was taking warfarin at a dose of 5 mg for
mitral valve disease as well as a diuretic and digoxin. He had not
been exposed to any trauma.
On physical examination, no haemorrhagea was observed
other than that of lingual haematoma (fig 1). Laboratory
examinations showed an international normalised ratio of
50.15, a haemoglobin value of 8.7 g/dl. Nasal oxygen, 5 IU
fresh frosen plasma, 2 U erythrocyte suspension and 20 mg
vitamin K were given to the patient. Two days later, the lingual
haematoma had disappeared.
Haemorrhageas caused by warfarin overdose usually appear
in the genitourinary, gastrointestinal, retroperitoneal and
intracranial areas. In the literature, 10 cases have so far been
reported, including sublingual and retropharyngeal haemorrha-
gea. This is the first isolated lingual haematoma observed on a
normal warfarin dose without overdosing, according to our
knowledge, to be reported in the literature.
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Figure 1 Lingual haematoma caused by usual warfarin dose. Informed
consent was obtained for publication of this figure.
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